JVS-100
/ Juventas Therap, Astellas
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
August 20, 2012
Juventas Therapeutics doses first patient in Phase 2 STOP-HF trial
(PRNewswire)
- P1, N=17; NCT01082094; Juventas reported 12-month results from P1 clinical trial in NYHA class 3 HF pts; In addition to meeting the primary safety endpoint, pts receiving target therapeutic doses demonstrated clinically significant improvement at 12 months in 6MWD & the MLHFQ; P2, N=90; STOP-HF; Juventas reports treating the first patient in STOP-HF trial
P1 data • Trial status • Heart Failure
October 22, 2014
Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure
(clinicaltrials.gov)
- P1/2; N=72; Active, not recruiting; Sponsor: Juventas Therapeutics, Inc.; Recruiting -> Active, not recruiting ; Trial primary completion date: Oct 2014 ->Aug 2015
Enrollment closed • Trial primary completion date • Acute Coronary Syndrome • Biosimilar • Dyslipidemia • Heart Failure • Reperfusion Injury
November 07, 2012
Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by trans-endocardial injection in patients with ischemic cardiomyopathy: The POSEIDON randomized trial
(JAMA)
- P1/2, N=30; NCT01087996; In pts with ICM, transendocardial injection of allogeneic & autologous MSCs without a PBO control were both associated with low rates of treatment-emergent SAEs, including immunologic reactions; In aggregate, MSC injection favorably affected patient functional capacity, QOL & ventricular remodeling
P1/2 data • Heart Failure
November 18, 2019
Intra-tracheal administration of a naked plasmid expressing stromal derived factor-1 improves lung structure in rodents with experimental bronchopulmonary dysplasia.
(PubMed, Respir Res)
- "Intratracheal administration of a naked plasmid expressing SDF-1 improves alveolar and vascular structure in an experimental model of BPD. These findings suggest that therapies which modulate lung SDF-1 expression may have beneficial effects in preterm infants with BPD."
Journal • Bronchopulmonary Dysplasia • Idiopathic Pulmonary Fibrosis • Immunology • Interstitial Lung Disease • Ophthalmology • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Retinal Disorders • Retinopathy of Prematurity
February 23, 2019
SDF-1 plasmid treatment for patients with peripheral artery disease (STOP-PAD): Randomized, double-blind, placebo-controlled clinical trial.
(PubMed, Vasc Med)
- P2b; "...Using a novel design, we examined the impact of complementing revascularization therapy with intramuscular JVS-100 - a non-viral gene therapy that activates endogenous regenerative repair pathways...Only one-quarter of CLI wounds healed at 3 months despite successful revascularization, highlighting the need for additional research in therapies that can improve microcirculation in these patients. ClinicalTrials.gov Identifier: NCT02544204."
Clinical • Journal
1 to 5
Of
5
Go to page
1